Survey of people's experiences using injectable semaglutide for weight management
Surveys adults who use injected semaglutide to manage obesity.
Plain-language title generated from the registry record
Registry title: Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.
Key facts
- Where
- Bad Oeynhausen, GermanySee the site
Where in Germany
- Bad OeynhausenBad Oeynhausen, GermanyNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Novo Nordisk A/S
- Trial code
- NCT07154238
- Record updated
- 25 November 2025
- Original description
The purpose of this study is to collect information for scientific research and to better understand the experiences of participants managing their weight. The study aims to collect valid responses through online interviews from participants. This study is a survey-based study without collection of laboratory data. Duration of the study will be about 14 months.Read full original descriptionShow less
Characteristics and Treatment Experiences of Individuals Using Injectable Semaglutide for Weight Management, a Cross-sectional Time-series Analysis, Multi-country Study.
The purpose of this study is to collect information for scientific research and to better understand the experiences of participants managing their weight. The study aims to collect valid responses through online interviews from participants. This study is a survey-based study without collection of laboratory data. Duration of the study will be about 14 months.
Inclusion: For an eligible participant (individuals initiated on injectable semaglutide for weight management), all inclusion criteria must be answered "yes"; Electronically provided consent obtained before any study-related activities can be completed; Age above or equal to 18 years at the time of providing informed consent; Reside in a participating country: Australia, Germany, United Arab Emirates (UAE) and Spain; Have been prescribed and initiated injectable semaglutide for weight management prior to study screening; For an eligible participant (HCPs), all inclusion criteria must be answered "yes"; Electronically provided consent obtained before any study-related activities can be completed; Practice in a participating country: Australia, Germany, UAE, and Spain; See at least 150 patients for any condition per month; priority given to those who treat at least 200 patients for any condition per month; Treat at least 10 adult patients per month for weight management; Prescribe anti-obesity medications (AOMs) to their patients they personally treat for weight management/obesity care; priority given to those who treat at least 10% of the patients they personally treat for weight management/obesity care with anti-obesity medications (AOMs); Prescribe injectable semaglutide for weight management; Be a specialty of interest (varies by country); mix of primary care, specialists such as Endocrinologists, Diabetologists, Nutrition Specialists, Obesity Specialists and others.
Exclusion: For an eligible participant (HCPs), all exclusion criteria must be answered "no"; Prior participation in this study. Participation is defined as having given informed consent and submitting responses to an interview; Unwillingness or language barriers precluding adequate understanding or cooperation; Only treats patients under 18 years of age; For an eligible participant (individuals initiated on injectable semaglutide for weight management), all exclusion criteria must be answered "no"; Unwillingness or language barriers precluding adequate understanding or cooperation; Is currently or planning to become pregnant in next six months; Is taking injectable semaglutide for Type 2 diabetes management only.